Karos Pharmaceuticals, a start-up focused on the selective modulation of peripheral serotonin synthesis, recently reported positive results from its Phase…
Articles by Patrícia Silva, PhD
Bayer and the Canadian Vascular Network (CVN) recently announced the winners of a joint research fellowship that provides recognition and…
Actelion Pharmaceuticals recently announced that Swissmedic, the Swiss regulatory agency for therapeutic products, has approved the orally active, selective IP…
The Pulmonary Hypertension Association (PHA) recently accredited the University of Rochester (UR) Medical Center as a Comprehensive Care Center, recognizing…
Eiger BioPharmaceuticals recently reported the dosing of a first patient in its Phase 2 LIBERTY clinical trial, evaluating the…
Actelion will soon start a Phase 3 clinical trial to assess the effectiveness of Opsumit (macitentan) in delaying the progression of pulmonary arterial…
PHAware is a project for pulmonary hypertension (PH) patients, loved ones, caregivers, medical professionals and other advocates which has gained great…
The Pulmonary Hypertension Association (PHA) International PH Conference and Scientific Sessions in Dallas, Texas broke an attendance record for the…
The Pulmonary Hypertension Association (PHA) was awarded during its 12th International Conference and Scientific Sessions, in Dallas, two new grants…
Reata Pharmaceuticals has reported positive interim results from the extension Phase 2 LARIAT clinical trial assessing bardoxolone methyl for the treatment…
SteadyMed, Ltd., and the Pulmonary Hypertension Association (PHA) recently launched a new campaign, called PHenomenal, offering patients with pulmonary hypertension…
Bellerophon Therapeutics, Inc., announced the enrollment of the first patient with pulmonary arterial hypertension (PAH) in its Phase 3 INOvation-1 clinical…